Quick Answer
HALOZYME THERAPEUTICS, INC. reported Operating Income of $469.01 million for fiscal year 2025.
HALOZYME THERAPEUTICS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $469.01M | -15.0% |
| 2024 | $551.48M | +63.4% |
| 2023 | $337.57M | +26.2% |
| 2022 | $267.53M | -3.0% |
| 2021 | $275.90M | +91.3% |
| 2020 | $144.25M | +313.4% |
| 2019 | -$67.61M | +2.5% |
| 2018 | -$69.33M | -185.6% |
| 2017 | $81.00M | +197.3% |
| 2016 | -$83.21M | -203.1% |
| 2015 | -$27.45M | +56.5% |
| 2014 | -$63.04M | +21.6% |
| 2013 | -$80.43M | -50.0% |
| 2012 | -$53.62M | -170.3% |
| 2011 | -$19.84M | +63.4% |
| 2010 | -$54.26M | +7.2% |
| 2009 | -$58.46M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $217.92M | +33.5% | +7.6% |
| June 30, 2025 | $202.44M | +72.7% | +43.0% |
| March 31, 2025 | $141.53M | +48.1% | -13.3% |
| September 30, 2024 | $163.20M | +84.9% | +39.2% |
| June 30, 2024 | $117.23M | +24.1% | +22.7% |
| March 31, 2024 | $95.54M | +77.6% | +8.2% |
| September 30, 2023 | $88.28M | +6.0% | -6.5% |
| June 30, 2023 | $94.46M | +177.3% | +75.6% |
- HALOZYME THERAPEUTICS, INC. showed a decrease of -15.0% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, HALOZYME THERAPEUTICS, INC.’s operating income has grown by 902.3% (from -$58.46 million to $469.01 million).
- The most recent figure is from HALOZYME THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: